33 related articles for article (PubMed ID: 38751576)
1. Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis.
Lee SD; Betts KA; Xiaoyan Du E; Nie X; Gupte-Singh K; Ritter T
Crohns Colitis 360; 2024 Apr; 6(2):otae026. PubMed ID: 38751576
[TBL] [Abstract][Full Text] [Related]
2. Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab.
Chiorean M; Afzali A; Cross RK; Macaulay D; Griffith J; Wang A; Garcia-Horton V
Crohns Colitis 360; 2020 Apr; 2(2):otaa031. PubMed ID: 36777306
[TBL] [Abstract][Full Text] [Related]
3. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.
Feuerstein JD; Isaacs KL; Schneider Y; Siddique SM; Falck-Ytter Y; Singh S;
Gastroenterology; 2020 Apr; 158(5):1450-1461. PubMed ID: 31945371
[No Abstract] [Full Text] [Related]
4. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States.
Long MD; Smith TW; Dibonaventura M; Gruben D; Bargo D; Salese L; Quirk D
Inflamm Bowel Dis; 2020 May; 26(6):941-948. PubMed ID: 31560046
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C;
N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence.
Gemayel NC; Rizzello E; Atanasov P; Wirth D; Borsi A
Curr Med Res Opin; 2019 Nov; 35(11):1911-1923. PubMed ID: 31192706
[No Abstract] [Full Text] [Related]
7. ACG Clinical Guideline: Ulcerative Colitis in Adults.
Rubin DT; Ananthakrishnan AN; Siegel CA; Sauer BG; Long MD
Am J Gastroenterol; 2019 Mar; 114(3):384-413. PubMed ID: 30840605
[TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.
Brady JE; Stott-Miller M; Mu G; Perera S
Clin Ther; 2018 Sep; 40(9):1509-1521.e5. PubMed ID: 30126706
[TBL] [Abstract][Full Text] [Related]
9. Defining Failure of Medical Therapy for Inflammatory Bowel Disease.
Volk N; Siegel CA
Inflamm Bowel Dis; 2019 Jan; 25(1):74-77. PubMed ID: 30016434
[TBL] [Abstract][Full Text] [Related]
10. Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey.
Yarlas A; Rubin DT; Panés J; Lindsay JO; Vermeire S; Bayliss M; Cappelleri JC; Maher S; Bushmakin AG; Chen LA; DiBonaventura M
J Crohns Colitis; 2018 Apr; 12(5):600-609. PubMed ID: 29718244
[TBL] [Abstract][Full Text] [Related]
11. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
Singh S; Fumery M; Sandborn WJ; Murad MH
Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
[TBL] [Abstract][Full Text] [Related]
12. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
Yu H; MacIsaac D; Wong JJ; Sellers ZM; Wren AA; Bensen R; Kin C; Park KT
Aliment Pharmacol Ther; 2018 Feb; 47(3):364-370. PubMed ID: 29164650
[TBL] [Abstract][Full Text] [Related]
13. Ulcerative Colitis Treatment Patterns and Cost of Care.
Null KD; Xu Y; Pasquale MK; Su C; Marren A; Harnett J; Mardekian J; Manuchehri A; Healey P
Value Health; 2017 Jun; 20(6):752-761. PubMed ID: 28577692
[TBL] [Abstract][Full Text] [Related]
14. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States.
Patel H; Lissoos T; Rubin DT
PLoS One; 2017; 12(4):e0175099. PubMed ID: 28426675
[TBL] [Abstract][Full Text] [Related]
15. Update on the Use of Biologic Therapy in Ulcerative Colitis.
Aggarwal A; Sabol T; Vaziri H
Curr Treat Options Gastroenterol; 2017 Mar; 15(1):155-167. PubMed ID: 28120279
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.
Taxonera C; Iglesias E; Muñoz F; Calvo M; Barreiro-de Acosta M; Busquets D; Calvet X; Rodríguez A; Pajares R; Gisbert JP; López-Serrano P; Pérez-Calle JL; Ponferrada Á; De la Coba C; Bermejo F; Chaparro M; Olivares D; Alba C; Fernández-Blanco I
Dig Dis Sci; 2017 Feb; 62(2):481-490. PubMed ID: 27995400
[TBL] [Abstract][Full Text] [Related]
17. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
Sands BE; Sandborn WJ; Van Assche G; Lukas M; Xu J; James A; Abhyankar B; Lasch K
Inflamm Bowel Dis; 2017 Jan; 23(1):97-106. PubMed ID: 27930408
[TBL] [Abstract][Full Text] [Related]
18. Etiology and Treatment of Pain and Psychosocial Issues in Patients With Inflammatory Bowel Diseases.
Regueiro M; Greer JB; Szigethy E
Gastroenterology; 2017 Feb; 152(2):430-439.e4. PubMed ID: 27816599
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
